Home > Oncology > ESMO 2023 > ESMO 2023 Highlights Podcast

ESMO 2023 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
ESMO 2023

In this episode (19:37), Medicom’s correspondent covers 6 presentations from the annual meeting of the European Society of Medical Oncology 2023, 20–24 October, held in Madrid, Spain.
The topics discussed are:

  1. Durvalumab climbs the MATTERHORN of gastric cancer
    The addition of PD-L1 inhibitor durvalumab to chemotherapy shows positive findings for pathological complete response (pCR) rate when given in the perioperative setting for patients with untreated, resectable gastric/gastro-oesophageal junction (GC/GEJ) cancers, results from MATTERHORN show. The impact on survival is still uncertain.
  2.  NICHE-3 demonstrates equally impressive results as NICHE-2
    Last year, NICHE-2 showed impressive pathological response rates of neoadjuvant nivolumab/ipilimumab in patients with mismatch repair deficient (dMMR) colon cancer, Now, NICHE-3 shows equally impressive pathological response rates after nivolumab/relatlimab neoadjuvant treatment of dMMR colon cancer.
  3. Benefit of pembrolizumab in TNBC remains after 5 years follow up
    The addition of pembrolizumab to both neoadjuvant and adjuvant chemotherapy improves event-free survival in patients with early triple-negative breast cancer (TNBC), as updated results of KEYNOTE-522 show.
  4. EV/pembrolizumab raises the bar for OS in metastatic urothelial cancer
    First-line treatment with enfortumab vedotin (EV) combined with pembrolizumab significantly improved progression-free (PFS) and overall survival (OS) in patients with locally advanced or metastatic urothelial cancer, as was shown by the results of the EV-302/KEYNOTE-A39 trial.
  5. Short (and cost-effective) induction chemotherapy hugely improves survival in advanced cervical cancer
    The addition of 6 cycles of carboplatin/paclitaxel induction chemotherapy, directly followed by standard chemoradiotherapy improved progression-free and overall survival in participants with locally advanced cervical cancer by almost 40%, results of phase 3 INTERLACE trial show.
  6. Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer
    Patients with KRASG12C-mutated, metastatic colorectal cancer (CRC) benefit from treatment with the combination of sotorasib, a KRASG12C mutation-selective inhibitor, and the EGFR-inhibitor panitumumab, first results from the phase 3 CodeBreak 300 trial show. Overall survival data is not yet mature

Enjoy listening!
Copyright ©2023 Medicom Medical Publishers

Posted on